Dr. Oesterheld’s comment: This study supports the value of genetic CYP2D6 testing when a patient on venlafaxine has difficulty tolerating a low dose (75Mg) of the drug. Mayo Clin Proc. 2007 Sep;82(9):1065-8. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. McAlpine DE, O’Kane DJ, Black JL, Mrazek DA. Department of Psychiatry and Psychology, Mayo Clinic, [...]
Filed under: Cytochrome P450, Drug Interactions, Personalized Medicine, Pharmacogenetics | Leave a Comment »
